385.18 USD
-3.19
0.82%
At close Feb 14, 4:00 PM EST
After hours
385.18
+0.00
0.00%
1 day
-0.82%
5 days
-1.94%
1 month
6.17%
3 months
0.50%
6 months
15.78%
Year to date
7.38%
1 year
10.23%
5 years
73.86%
10 years
305.15%
 

About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Employees: 53,000

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

90% more first-time investments, than exits

New positions opened: 152 | Existing positions closed: 80

2% more funds holding

Funds holding: 1,949 [Q2] → 1,991 (+42) [Q3]

10% more repeat investments, than reductions

Existing positions increased: 781 | Existing positions reduced: 712

4% more capital invested

Capital invested by funds: $106B [Q2] → $110B (+$4.09B) [Q3]

9% less call options, than puts

Call options by funds: $586M | Put options by funds: $641M

1.61% less ownership

Funds ownership: 81.69% [Q2] → 80.07% (-1.61%) [Q3]

3% less funds holding in top 10

Funds holding in top 10: 77 [Q2] → 75 (-2) [Q3]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$413
7%
upside
Avg. target
$437
14%
upside
High target
$450
17%
upside

11 analyst ratings

positive
82%
neutral
18%
negative
0%
Barclays
Matt Miksic
82% 1-year accuracy
31 / 38 met price target
15%upside
$443
Overweight
Maintained
10 Feb 2025
Goldman Sachs
David Roman
54% 1-year accuracy
7 / 13 met price target
11%upside
$427
Neutral
Maintained
30 Jan 2025
Truist Securities
Richard Newitter
74% 1-year accuracy
31 / 42 met price target
7%upside
$413
Hold
Maintained
30 Jan 2025
RBC Capital
Shagun Singh
61% 1-year accuracy
41 / 67 met price target
13%upside
$435
Outperform
Maintained
29 Jan 2025
Wells Fargo
Larry Biegelsen
63% 1-year accuracy
30 / 48 met price target
13%upside
$435
Overweight
Maintained
29 Jan 2025

Financial journalist opinion

Based on 23 articles about SYK published over the past 30 days

Neutral
PRNewsWire
2 days ago
Kadant Set to Join S&P SmallCap 600
NEW YORK , Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE: KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE: SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.
Kadant Set to Join S&P SmallCap 600
Neutral
GlobeNewsWire
3 days ago
Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.
Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Neutral
GlobeNewsWire
6 days ago
Stryker announces Allan Golston will retire from Board of Directors
Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025.  Golston joined Stryker's Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees. “We are grateful for Allan's many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We thank Allan for his leadership and dedication in helping Stryker advance our mission of making healthcare better.” Golston has served as the President, United States Program for the Bill & Melinda Gates Foundation since 2006, and as Chief Financial and Administrative Officer of the Bill & Melinda Gates Foundation from 2000 to 2006. He is also a director of Harley-Davidson, Inc., a manufacturer of motorcycles and accessories. Golston has extensive experience in auditing, finance and the healthcare industry. He is a certified public accountant and has held hospital finance executive positions. In his service to the Gates Foundation, he has contributed to the strategic formation and operation of successful initiatives to provide healthcare, education and other human needs, all of which gave him an understanding that assisted Stryker in its global efforts to meet the needs of patients and caregivers. About Stryker
Stryker announces Allan Golston will retire from Board of Directors
Positive
FXEmpire
2 weeks ago
Sales Growth, Strategic Acquisitions Drive Stryker Higher
Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.
Sales Growth, Strategic Acquisitions Drive Stryker Higher
Positive
Zacks Investment Research
2 weeks ago
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
Positive
Benzinga
2 weeks ago
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Positive
Benzinga
2 weeks ago
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Neutral
Zacks Investment Research
2 weeks ago
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Negative
Zacks Investment Research
2 weeks ago
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
Neutral
Seeking Alpha
2 weeks ago
Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript
Stryker Corporation (NYSE:SYK ) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neurotechnology Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Companies Shagun Singh - RBC Matthew Miksic - Barclays Michael Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Josh Jennings - TD Cowen Danielle Antalffy - UBS Equities Michael Polark - Wolfe Research Operator Welcome to the Fourth Quarter 2024 Stryker Earnings Call. My name is Luke, and I'll be your operator for today's call.
Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript
Charts implemented using Lightweight Charts™